Literature DB >> 21570483

Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.

Jacqueline G O'Leary1, Carmen Landaverde, Linda Jennings, Robert M Goldstein, Gary L Davis.   

Abstract

BACKGROUND & AIMS: Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT).
METHODS: We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646).
RESULTS: Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group (P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis.
CONCLUSIONS: Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570483      PMCID: PMC4408909          DOI: 10.1016/j.cgh.2011.04.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  28 in total

1.  The liver in obesity.

Authors:  S ZELMAN
Journal:  AMA Arch Intern Med       Date:  1952-08

2.  Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.

Authors:  Kanthi Yalamanchili; Sherif Saadeh; Göran B Klintmalm; Linda W Jennings; Gary L Davis
Journal:  Liver Transpl       Date:  2010-04       Impact factor: 5.799

3.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

4.  Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation.

Authors:  Gamze Ayata; Fredric D Gordon; W David Lewis; Elizabeth Pomfret; James J Pomposelli; Roger L Jenkins; Urmila Khettry
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

5.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

Authors:  Leon A Adams; Schuyler Sanderson; Keith D Lindor; Paul Angulo
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

Review 6.  Indications for liver transplantation.

Authors:  Jacqueline G O'Leary; Rita Lepe; Gary L Davis
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

7.  Outcome after liver transplantation for NASH cirrhosis.

Authors:  S M Malik; M E deVera; P Fontes; O Shaikh; J Ahmad
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

Review 8.  Nonalcoholic fatty liver disease and liver transplantation.

Authors:  Paul Angulo
Journal:  Liver Transpl       Date:  2006-04       Impact factor: 5.799

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

Authors:  Abigail Fraser; Matthew P Longnecker; Debbie A Lawlor
Journal:  Gastroenterology       Date:  2007-09-02       Impact factor: 22.682

View more
  24 in total

Review 1.  Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.

Authors:  Adnan Said
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.

Authors:  Veronica Wendy Setiawan; Daniel O Stram; Jacqueline Porcel; Shelly C Lu; Loïc Le Marchand; Mazen Noureddin
Journal:  Hepatology       Date:  2016-07-17       Impact factor: 17.425

Review 3.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

Review 4.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

Review 5.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

6.  Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation.

Authors:  Joseph Ahn; Benny Liu; Taft Bhuket; Robert J Wong
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

7.  Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.

Authors:  Robert D Mair; Antonia Valenzuela; Nghiem B Ha; Walid S Ayoub; Tami Daugherty; Glen A Lutchman; Gabriel Garcia; Aijaz Ahmed; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

Review 8.  Acute-on-chronic liver failure.

Authors:  Sumeet K Asrani; Jacqueline G O'Leary
Journal:  Clin Liver Dis       Date:  2014-08       Impact factor: 6.126

9.  Weight loss interventions for morbidly obese patients with compensated cirrhosis: a Markov decision analysis model.

Authors:  Bianca Bromberger; Paige Porrett; Rashikh Choudhury; Kristoffel Dumon; Kenric M Murayama
Journal:  J Gastrointest Surg       Date:  2013-08-06       Impact factor: 3.452

Review 10.  Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.

Authors:  Yuval A Patel; Carl L Berg; Cynthia A Moylan
Journal:  Dig Dis Sci       Date:  2016-01-27       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.